

Cutaneous Melanoma Risk Assessment Algorithmic Tests

- I. Cutaneous melanoma risk assessment algorithmic tests are considered **medically necessary** when:
 - A. The member has a melanocytic neoplasm that shows at least one ABCDE feature (asymmetry, border irregularity, color variegation, diameter greater than 6 mm, and evolution), **AND**
 - B. A biopsy is being considered but has not yet been performed, **AND**
 - C. The use of the test is limited to a maximum of 2 times per visit.
- II. Cutaneous melanoma risk assessment algorithmic tests are considered **investigational** for all other indications.

DEFINITIONS

1. **ABCDE feature** is an acronym for examining patients with a lesion that is suspicious for melanoma: asymmetry, border irregularity, color variegation, diameter greater than 6 mm, and evolution.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

2. Swetter, SS, Tsao, HH, Bichakjian, CC, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250. doi:10.1016/j.jaad.2018.08.055.
3. Swetter, S and Geller, A. Melanoma: Clinical features and diagnosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. Accessed November 1, 2024. <https://www.uptodate.com/contents/melanoma-clinical-features-and-diagnosis>
4. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MolDX: Pigmented Lesion Assay (L38051). Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38051&ver=17&>
5. ECRI. Pigmented Lesion Assay (DermTech) for Aiding Melanoma Diagnosis. Genetic Test Assessment. 2023 March.